UNSPSC 51293607: Ciclindole or cyclindole

This classification denotes an antidepressant agent with the molecular formula C14H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CXJ7G6BYD7, chemically known as 2,3,4,9-tetrahydro-n,n-dimethyl-1h-carbazol-3-amine but generally known as ciclindole, which bears US NIH Compound Identifier 36082. European Medicines Agency schedules Ciclindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06238MIG.

The term CICLINDOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). CICLINDOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ciclindole or cyclindole bears US NLM identifiers UMLS ID C0056704 and NCI Concept Code C81488. SMILES: N(C1Cc2c([nH]c3c2cccc3)CC1)(C)C.

UNSPSC 51293607 Ciclindole or cyclindole is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local solicitations tagged under this code do not reflect procurement of that substance. Instead, the opportunities posted show demand for naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs — a material mismatch between the code's name and the work actually being bought. The issuing bodies span health departments and cooperative purchasing alliances: Seminole County, Florida (a county health department) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration, alongside the Texas Health and Human Services Commission (a state agency). The scope consists of emergency opioid-reversal medication supply, generic pharmaceutical product distribution to state and local facilities across multiple states, and vendor qualification for direct contracting between pharmacy programs and manufacturers.

Geographic activity concentrates in Florida, Minnesota, and Texas, with MMCAP participation extending to Oregon. Recent opportunities include an IFB from Seminole County, Florida (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; an RFP from MMCAP (Solicitation S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with contract start July 1, 2026; and a Request for Information from the Texas Health and Human Services Commission (Solicitation HHS0017013, posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Given the disconnect between the code's specific chemical name and the actual pharmaceutical procurement activity, this code appears to contain miscategorized opportunities rather than true ciclindole sourcing.